| |
Patients (n)
|
CR (%)
|
PR (%)
|
SD (%)
|
PD (%)
|
|---|
|
Overall
|
31
|
1 (3.2)
|
9 (29)
|
12 (38.8)
|
9 (29)
|
|
2nd and 3rd line
|
11
|
0 (0)
|
5 (45.5)
|
6 (55.5)
|
0 (0)
|
|
4th and later line
|
20
|
1 (5)
|
4 (20)
|
6 (30)
|
9 (45)
|
|
FOLFIRI
|
19
|
1 (5.3)
|
6 (31.6)
|
8 (42.1)
|
4 (2.1)
|
|
FOLFOX
|
12
|
0 (0)
|
3 (25)
|
4 (33.3)
|
5 (41.7)
|
|
Same CT previously used
| | | | | |
|
Yes
|
29
|
1 (3.5)
|
9 (31)
|
11 (37.9)
|
8 (27.6)
|
|
No
|
2*
|
0 (0)
|
0 (0)
|
1 (50)
|
1 (50)
|
- CR; complete response, CT; chemotherapy; PR; partial response, SD; stable disease, PD; progression disease. * no previous treatment by FOLFOX in two patients treated by bevacizumab + FOLFOX
